Difference between revisions of "S-444,823"
From Wiki Weed
(Created page with "S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. It was developed as an antipruritic, and has moderate selectivity for the CB2 subtype, having...") |
|||
| Line 1: | Line 1: | ||
| − | S-444,823 is a drug developed by Shionogi which is a [[cannabinoid]] agonist. It was developed as an antipruritic, and has moderate selectivity for the [[CB2]] subtype, having a CB2 affinity of 18nM, and 32x selectivity over the [[CB1]] receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists. | + | '''S-444,823''' is a drug developed by Shionogi which is a [[cannabinoid]] agonist. It was developed as an antipruritic, and has moderate selectivity for the [[CB2]] subtype, having a CB2 affinity of 18nM, and 32x selectivity over the [[CB1]] receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists. |
Latest revision as of 04:06, 15 February 2015
S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. It was developed as an antipruritic, and has moderate selectivity for the CB2 subtype, having a CB2 affinity of 18nM, and 32x selectivity over the CB1 receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists.
